The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.08 (1.31%)
Spread: 1.48 (26.812%)
Open: 6.20
High: 6.20
Low: 6.20
Prev. Close: 6.12
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tuesday broker round-up UPDATE

Tue, 21st Oct 2014 08:50

African Barrick Gold: JP Morgan cuts target price from 340p to 300p and stays with its overweight rating.Anglo American: JP Morgan raises target price from 1240p to 1310p, while leaving its underweight rating unchanged. Investec increases target price from 1573p to 1603p and stays with its buy recommendation.Antofagasta: JP Morgan reduces target price from 830p to 760p maintaining a neutral rating.BHP Billiton: JP Morgan reduces target price from 2250p to 2180p keeping a neutral rating.Brooks Macdonald: Numis reduces target price from 1550p to 1470p retaining its hold recommendation.Brown (N) Group: Credit Suisse reduces target price from 518p to 330p downgrading to neutral.BT Group: Goldman Sachs cuts target price from 620p to 600p retaining a strong buy recommendation.Cable & Wireless Communications: JP Morgan lowers target price from 53p to 50p and maintains a neutral rating.Dairy Crest: UBS cuts target price from 460p to 410p retaining a neutral rating.Devro: N+1 Singer upgrades from hold to buy with a target price of 257p.Dialight: Investec upgrades from sell to hold with a target price of 850p.GKN: JP Morgan reduces target price from 460p to 370p reiterating its overweight rating.Go Ahead Group: Investec increases target price from 2670p to 2750p and leaves its buy recommendation unchanged.Hellermann Tyton: UBS initiates with a target price of 300p and a neutral rating.Hochschild Mining: JP Morgan cuts target price from 185p to 150p keeping its neutral rating.Informa: Westhouse Securities upgrades from neutral to buy with a target price of 554p.Inmarsat: JP Morgan ups target price from 810p to 840p and reiterates an overweight rating.Kazakhmys: JP Morgan cuts target price from 400p to 375p and stays with its overweight rating.Lloyds Banking Group: Credit Suisse shifts target price from 68p to 72p and stays with its neutral rating.NMC Health: Investec initiates with a target price of 610p and a buy recommendation.Petropavlovsk: JP Morgan lowers target price from 20p to 10p and reiterates an underweight rating.President Energy: Canaccord Genuity moves target price from 50p to 60p and retains its speculative buy recommendation.Redefine: Deutsche Bank lowers target price from 56p to 53p keeping its hold recommendation.Rightmove: Credit Suisse reduces target price from 3100p to 2655p and reiterates an outperform rating.Standard Chartered: Credit Suisse reduces target price from 1150p to 1020p and maintains an underperform rating.Synairgen: N+1 Singer initiates with a target price of 49p and a buy recommendation.Talk Talk Telecom: Goldman Sachs cuts target price from 450p to 435p and maintains a buy recommendation.Telecity Group: JP Morgan ups target price from 900p to 925p and keeps an overweight rating.Travis Perkins: UBS reduces target price from 2100p to 2000p reiterating a buy recommendation. Deutsche Bank lowers target price from 1901p to 1898p and keeps its hold recommendation.Vedanta Resources: JP Morgan reduces target price from 1130p to 1030p and retains a neutral rating.William Hill: Canaccord Genuity moves target price from 350p to 365p and keeps a hold recommendation.Zoopla Property: Credit Suisse cuts target price from 290p to 270p leaving its outperform rating unaltered.
More News
22 Jul 2015 10:44

AstraZeneca starts next phase of testing on Synairgen asthma drug

(ShareCast News) - Synairgen announced AstraZeneca started another phase of testing on its asthma drug. AIM listed Synairgen said AstraZeneca begun its Phase IIa trial of the drug AZD9412 and expected results in early 2017. AstraZeneca would test 220 asthma patients whose conditions were exacerbate

Read more
22 Jul 2015 07:00

Synairgen Says AstraZeneca Begins Phase IIa Trial In Severe Asthma

Read more
22 Jun 2015 07:28

LONDON BRIEFING: Stocks Surge On Optimism For Greek Debt Deal

Read more
22 Jun 2015 05:13

AGM, EGM Calendar - Week Ahead

Read more
19 Jun 2015 15:14

AGM, EGM Calendar - Week Ahead

Read more
19 Jun 2015 05:21

AGM, EGM Calendar - Week Ahead

Read more
18 Jun 2015 15:06

AGM, EGM Calendar - Week Ahead

Read more
18 Jun 2015 05:27

AGM, EGM Calendar - Week Ahead

Read more
17 Jun 2015 14:56

AGM, EGM Calendar - Week Ahead

Read more
17 Jun 2015 05:23

AGM, EGM Calendar - Week Ahead

Read more
16 Jun 2015 15:03

AGM, EGM Calendar - Week Ahead

Read more
16 Jun 2015 05:23

AGM, EGM Calendar - Week Ahead

Read more
15 Jun 2015 14:52

AGM, EGM Calendar - Week Ahead

Read more
3 Mar 2015 08:38

Synairgen Swings To 2014 Pretax Profit On AstraZeneca Licence Deal

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.